Investigation of a possible interaction between quetiapine and armodafinil in patients with schizophrenia: An open-label, multiple-dose study

Journal of Clinical Pharmacology

Volumn 52, Issue 9, 2012, Pages 1399-1409

  Darwish, Mona ^a   Bond, Mary ^a   Hellriegel, Edward T ^b   Youakim, James M ^a   Yang, Ronghua ^a   Robertson, Philmore ^b  

^a Cephalon Inc   (United States)

^b CEPHALON INC   (United States)

Author keywords

Armodafinil; drug drug interactions; pharmacokinetics; quetiapine; schizophrenia

Indexed keywords

ARMODAFINIL; QUETIAPINE;

ADULT; AGITATION; ANOREXIA; ANXIETY; APPLICATION SITE EXCORIATION; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; AUDITORY HALLUCINATION; CATATONIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ERUPTION; EVENING DOSAGE; FEMALE; HUMAN; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; MENTAL PATIENT; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOPHARMACOTHERAPY; RHINOPHARYNGITIS; SCHIZOPHRENIA; SIDE EFFECT; STEADY STATE; STOMACH DISCOMFORT; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; VOMITING; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DIBENZOTHIAZEPINES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84865324082     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011414572     Document Type: Article

References (33)

1. Czeisler CA, Walsh JK, Wesnes KA, et al. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc. 2009 ; 84: 958-972
2. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006 ; 22: 761-774
3. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther.. 2006 ; 28: 689-706
4. Hirshkowitz M, Black JE, Wesnes K, Niebler G, Arora S, Roth T. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med. 2007 ; 101: 616-627
5. Kane JM, D'Souza DC, Patkar AA, et al. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J Clin Psychiatry. 2010 ; 71: 1475-1481
6. Robertson P, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003 ; 42: 123-137
7. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol. 1999 ; 39: 30-40
8. Darwish M, Kirby M, Hellriegel ET, Yang R, Robertson P. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. Clin Drug Investig. 2009 ; 29: 87-100
9. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol. 1999 ; 39: 281-288
10. Frazer, PA: Cephalon, Inc ; 2008 :
11. Darwish M, Kirby M, Hellriegel ET, Robertson P. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig. 2009 ; 29: 613-623
12. Darwish M, Kirby M, Hellriegel ET. Comparison of steady-state plasma concentrations of armodafinil and modafinil late in the day following morning administration: post hoc analysis of two randomized, double-blind, placebo-controlled, multiple-dose studies in healthy male subjects. Clin Drug Investig. 2009 ; 29: 601-612
13. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006 ; 32: 214-219
14. Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?. Acta Psychiatr Scand. 2007 ; 115: 93-100
15. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology. 2004 ; 29: 1363-1373
16. Hunter MD, Ganesan V, Wilkinson ID, Spence SA. Impact of modafinil on prefrontal executive function in schizophrenia. Am J Psychiatry. 2006 ; 163: 2184-2186
17. Sevy S, Rosenthal MH, Alvir J, et al. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry. 2005 ; 66: 839-843
18. Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry. 2009 ; 70: 104-112
19. Pierre JM, Peloian JH, Wirshing DA, Wirshing WC, Marder SR. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry. 2007 ; 68: 705-710
20. Cheer SM, Wagstaff AJ. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs. 2004 ; 18: 173-199
21. Baldwin CM, Scott LJ. Quetiapine extended release: in schizophrenia. CNS Drugs. 2009 ; 23: 261-269
22. Wilmington, DE: AstraZeneca Pharmaceuticals LP ; 2009:
23. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006 ; 61: 58-69
24. Darwish M, Kirby M, Robertson P, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008 ; 47: 61-74
25. Diagnostic and Statistical Manual of Mental Disorders. 4 th ed.Washington, DC: American Psychiatric Association; 2000. Washington, DC: American Psychiatric Association ; 2000:
26. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Guideline for good clinical practice, E6(R1). Current step 4 version, dated 10 June 1996. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf. Accessed June 24, 2011.
27. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 ; 353: 1209-1223
28. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001 ; 40: 509-522
29. Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvanitis LA. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol. 2002 ; 22: 121-130
30. Potkin SG, Thyrum PT, Alva G, et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol. 2002 ; 22: 174-182
31. Wong YW, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol. 2001 ; 21: 89-93
32. Kane J, Youakim J, Yang R, Tiller J. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study. Poster presented at: 7th Annual Scientific Meeting of the International Society for CNS Clinical Trials and Methodology (ISCTM) ; Washington, DC ;..
33. Meltzer HY. Serum creatine phosphokinase in schizophrenia. Am J Psychiatry. 1976 ; 133: 192-197